<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437618</url>
  </required_header>
  <id_info>
    <org_study_id>BRAF-0809-TRIBV</org_study_id>
    <nct_id>NCT01437618</nct_id>
  </id_info>
  <brief_title>First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer</brief_title>
  <official_title>FOLFOXIRI Plus Bevacizumab as First-line Treatment for BRAF V600E Mutant Metastatic Colorectal Cancer: a Prospective Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero, Universitaria Pisana</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to prospectively verify if FOLFOXIRI plus bevacizumab as&#xD;
      first-line treatment could be considered a promising approach to improve the outcome of BRAF&#xD;
      mutant metastatic colorectal cancer patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>About 24-30 months (From treatment initiation to evidence of progression or death from any cause)</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">15</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>BRAF mutant mCRC</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI plus bevacizumab</intervention_name>
    <description>BEVACIZUMAB 5 mg/Kg i.v. over 30', day 1 followed by&#xD;
IRINOTECAN 165 mg/sqm i.v. over 1-h, day 1 followed by&#xD;
OXALIPLATIN 85 mg/sqm i.v. over 2-h, day 1 concomitantly with&#xD;
l-LV 200 mg/sqm i.v. over 2-h, day 1 followed by&#xD;
5-FLUOROURACIL 3200 mg/sqm i.v. 48-h continuous infusion, starting on day 1 Cycles repeated every 2 weeks</description>
    <arm_group_label>BRAF mutant mCRC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        BRAF mutant mCRC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed colorectal adenocarcinoma;&#xD;
&#xD;
          -  Availability of formalin-fixed paraffin embedded tumor block from primary and/or&#xD;
             metastasis;&#xD;
&#xD;
          -  BRAF V600E mutant status of primary colorectal cancer and/or related metastasis;&#xD;
&#xD;
          -  Unresectable and measurable metastatic disease according to RECIST criteria;&#xD;
&#xD;
          -  Male or female, aged &gt; 18 years and &lt; 75 years;&#xD;
&#xD;
          -  ECOG PS &lt; 2 if aged &lt; 71 years;&#xD;
&#xD;
          -  ECOG PS = 0 if aged 71-75 years;&#xD;
&#xD;
          -  Life expectancy of more than 3 months;&#xD;
&#xD;
          -  Adequate haematological function: ANC ≥ 1.5 x 10^9/L; platelets ≥ 100 x 10^9/L, Hb ≥ 9&#xD;
             g/dL;&#xD;
&#xD;
          -  Adequate liver function: serum bilirubin ≤ 1.5 x ULN; alkaline phosphatase and&#xD;
             transaminases ≤ 2.5 x ULN (in case of liver metastases ≤ 5 x ULN);&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN;&#xD;
&#xD;
          -  Previous adjuvant chemotherapy is allowed if more than 12 months have elapsed between&#xD;
             the end of adjuvant therapy and first relapse;&#xD;
&#xD;
          -  At least 6 weeks from prior extended radiotherapy and 4 weeks from surgery;&#xD;
&#xD;
          -  Written informed consent to experimental treatment and molecular analyses.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence or history of CNS metastasis;&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture;&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy;&#xD;
&#xD;
          -  Uncontrolled hypertension;&#xD;
&#xD;
          -  Clinically significant (i.e. active) cardiovascular disease for example&#xD;
             cerebrovascular accidents (CVA) (≤6 months before treatment start), myocardial&#xD;
             infarction (≤ 6 months before treatment start), unstable angina, NYHA ≥ grade 2&#xD;
             chronic heart failure (CHF), uncontrolled arrhythmia;&#xD;
&#xD;
          -  Current or recent (within 10 days prior to study treatment start) ongoing treatment&#xD;
             with anticoagulants for therapeutic purposes;&#xD;
&#xD;
          -  Chronic, daily treatment with high-dose aspirin (&gt;325 mg/day);&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy ≥ 2 grade NCIC-CTG criteria;&#xD;
&#xD;
          -  Active uncontrolled infections;&#xD;
&#xD;
          -  Treatment with any investigational drug within 30 days prior to enrolment;&#xD;
&#xD;
          -  Other co-existing malignancies or malignancies diagnosed within the last 5 years with&#xD;
             the exception of curatively treated basal and squamous cell carcinoma of the skin or&#xD;
             in situ cancer of the cervix;&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to study treatment start;&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption&#xD;
             syndrome;&#xD;
&#xD;
          -  Fertile women (&lt; 2 years after last menstruation) and men of childbearing potential&#xD;
             not willing to use effective means of contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>July 12, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <last_update_submitted>September 20, 2011</last_update_submitted>
  <last_update_submitted_qc>September 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero, Universitaria Pisana</investigator_affiliation>
    <investigator_full_name>Alfredo Falcone</investigator_full_name>
    <investigator_title>Professor Alfredo Falcone</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

